Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18162805 | 0.82 | GAA (0.51) | GAALMNAKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL21994880 | 0.82 | GAA (0.54) | GAALMNAKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL21952349 | 0.82 | GAA (0.54) | GAALMNAKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL20099471 | 0.81 | SMN1; SMN2 (0.56) | GAALMNAKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL2201068 | 0.80 | GAA (0.57) | GAALMNAKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL18162791 | 0.78 | GAA (0.51) | GAALMNAKDM4ESMN1; SMN2ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL27041458 | 0.77 | GAA (0.47) | GAALMNAKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL20099453 | 0.77 | SMN1; SMN2 (0.50) | GAALMNAKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL9530620 | 0.76 | S1PR5 (0.38) | SMN1; SMN2 | |
| SCHEMBL23396624 | 0.74 | KEAP1 (0.55) | GAALMNAKDM4ESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10882883-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200262858-A1 | DERIVATIVES OF AMPHOTERICIN B | ELION THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| US-9957290-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957290-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20160304548-A1 | Derivatives of Amphotericin B | ELION THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304548-A1 | Derivatives of Amphotericin B | C9, ERG28, AMPD3 | GAA 1108/4885LMNA 2238/4885KDM4E 2646/4885 |
| US-10882883-B2 | Derivatives of amphotericin B | C9, ERG28, AMPD3 | GAA 1108/4885LMNA 2238/4885KDM4E 2646/4885 |
| US-20200262858-A1 | DERIVATIVES OF AMPHOTERICIN B | C9, ERG28, AMPD3 | GAA 1108/4885LMNA 2238/4885KDM4E 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.